Literature DB >> 20067544

Neutralization of LIGHT ameliorates acute dextran sodium sulphate-induced intestinal inflammation.

Michaela Jungbeck1, Barbara Daller, Josef Federhofer, Anja K Wege, Nadin Wimmer, Daniela N Männel, Thomas Hehlgans.   

Abstract

Emerging data indicate that alterations in the expression of tumour necrosis factor (TNF) superfamily members play a crucial role in the pathogenesis of intestinal inflammation. Recent results demonstrated that sustained transgenic expression of lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T cells (LIGHT; TNFSF14) induced severe intestinal inflammation, suggesting a specific role of LIGHT-mediated signalling to the intestinal compartment. In order to dissect the role of LIGHT in intestinal inflammation, we used LIGHT-deficient mice in the mouse model of acute dextran sodium sulphate-induced colitis. Interestingly, LIGHT-deficient mice were characterized by strongly reduced signs of intestinal inflammation compared with wild-type mice in this experimental model. Determination of mouse LIGHT mRNA expression in colon tissues of wild-type mice revealed a strong induction of mouse LIGHT mRNA expression during acute DSS-induced colitis. We therefore generated anti-mouse LIGHT monoclonal antibodies in LIGHT-deficient mice which bind specifically to LIGHT and are capable of neutralizing the activity of LIGHT in vitro and in vivo. With these antibodies, we demonstrated that neutralization of LIGHT during acute DSS-induced colitis resulted in reduced signs of intestinal inflammation. These data suggest that LIGHT is an important mediator in intestinal inflammation and may serve as a new target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20067544      PMCID: PMC2770692          DOI: 10.1111/j.1365-2567.2009.03131.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

Review 1.  Innate immunity in the pathogenesis and therapy of IBD.

Authors:  R Balfour Sartor
Journal:  J Gastroenterol       Date:  2003-03       Impact factor: 7.527

2.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

3.  Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway.

Authors:  K Tamada; K Shimozaki; A I Chapoval; G Zhu; G Sica; D Flies; T Boone; H Hsu; Y X Fu; S Nagata; J Ni; L Chen
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

4.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.

Authors:  D N Mauri; R Ebner; R I Montgomery; K D Kochel; T C Cheung; G L Yu; S Ruben; M Murphy; R J Eisenberg; G H Cohen; P G Spear; C F Ware
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

5.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

Authors:  I Okayasu; S Hatakeyama; M Yamada; T Ohkusa; Y Inagaki; R Nakaya
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

6.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

7.  LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.

Authors:  Y Zhai; R Guo; T L Hsu; G L Yu; J Ni; B S Kwon; G W Jiang; J Lu; J Tan; M Ugustus; K Carter; L Rojas; F Zhu; C Lincoln; G Endress; L Xing; S Wang; K O Oh; R Gentz; S Ruben; M E Lippman; S L Hsieh; D Yang
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

8.  LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine.

Authors:  Offer Cohavy; Jaclyn Zhou; Steve W Granger; Carl F Ware; Stephan R Targan
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

9.  Activation of the lymphotoxin-beta receptor induces NFkappaB-dependent interleukin-6 and MIP-2 secretion in mouse fibrosarcoma cells.

Authors:  Thomas Hehlgans; Peter Müller; Peter Stopfer; Daniela N Männel
Journal:  Eur Cytokine Netw       Date:  2003 Apr-Jun       Impact factor: 2.737

10.  Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis.

Authors:  P Stopfer; F Obermeier; N Dunger; W Falk; S Farkas; M Janotta; A Möller; D N Männel; T Hehlgans
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

View more
  10 in total

1.  The tumor necrosis factor family member TNFSF14 (LIGHT) is required for resolution of intestinal inflammation in mice.

Authors:  Petra Krause; Sonja P Zahner; Gisen Kim; Raziyah B Shaikh; Marcos W Steinberg; Mitchell Kronenberg
Journal:  Gastroenterology       Date:  2014-02-19       Impact factor: 22.682

2.  Realigning the LIGHT signaling network to control dysregulated inflammation.

Authors:  Carl F Ware; Michael Croft; Garry A Neil
Journal:  J Exp Med       Date:  2022-05-23       Impact factor: 17.579

3.  Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats.

Authors:  Altug Senol; Mehmet Isler; Recep Sutcu; Mete Akin; Ebru Cakir; Betul M Ceyhan; M Cem Kockar
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

4.  Therapeutic blockade of LIGHT interaction with herpesvirus entry mediator and lymphotoxin β receptor attenuates in vivo cytotoxic allogeneic responses.

Authors:  Maria-Luisa del Rio; Carlos Fernandez-Renedo; Stefanie Scheu; Klaus Pfeffer; Yasushi Shintani; Mitchell Kronenberg; Olivier Chaloin; Pascal Schneider; Jose-Ignacio Rodriguez-Barbosa
Journal:  Transplantation       Date:  2014-12-15       Impact factor: 4.939

5.  A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia.

Authors:  Helen M Marriott; Marc Daigneault; Alfred A R Thompson; Sarah R Walmsley; Sharonjit K Gill; Derrick R Witcher; Victor J Wroblewski; Paul G Hellewell; Moira K B Whyte; David H Dockrell
Journal:  Thorax       Date:  2012-06-26       Impact factor: 9.139

Review 6.  Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.

Authors:  Tomasz J Ślebioda; Zbigniew Kmieć
Journal:  Mediators Inflamm       Date:  2014-06-17       Impact factor: 4.711

7.  Tumor necrosis factor superfamily 14 is critical for the development of renal fibrosis.

Authors:  You Li; Ming Tang; Bo Han; Shun Wu; Shu-Jing Li; Qian-Hui He; Feng Xu; Gui-Qing Li; Kun Zhang; Xu Cao; Quan-You Zheng; Jian Chen; Di Yang; Gui-Lian Xu; Ke-Qin Zhang
Journal:  Aging (Albany NY)       Date:  2020-11-24       Impact factor: 5.682

8.  The delay in the development of experimental colitis from isomaltosyloligosaccharides in rats is dependent on the degree of polymerization.

Authors:  Hitoshi Iwaya; Jae-Sung Lee; Shinya Yamagishi; Aki Shinoki; Weeranuch Lang; Charin Thawornkuno; Hee-Kwon Kang; Yuya Kumagai; Shiho Suzuki; Shinichi Kitamura; Hiroshi Hara; Masayuki Okuyama; Haruhide Mori; Atsuo Kimura; Satoshi Ishizuka
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

9.  Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.

Authors:  Erik Andersson; Daniel Bergemalm; Robert Kruse; Gunter Neumann; Mauro D'Amato; Dirk Repsilber; Jonas Halfvarson
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  Metabolic activation and colitis pathogenesis is prevented by lymphotoxin β receptor expression in neutrophils.

Authors:  Thomas Riffelmacher; Daniel A Giles; Sonja Zahner; Martina Dicker; Alexander Y Andreyev; Sara McArdle; Tamara Perez-Jeldres; Esmé van der Gracht; Mallory Paynich Murray; Nadine Hartmann; Alexei V Tumanov; Mitchell Kronenberg
Journal:  Mucosal Immunol       Date:  2021-02-10       Impact factor: 7.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.